Submitted:
30 July 2023
Posted:
01 August 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Resources and Methodologies
2.1. Chemicals and Animals
2.2. Nanoparticles of Silver Nitrate with Vanillic Acid Coating (AgNPS)
2.3. Assessment of the Properties of Synthesized Vanillic acid Coated with AgNPs
2.3.1. Visualization of the AgNPs-Coated Vanillic acid in Transmission Electron Microscopy
2.3.2. Examination of UV-Visible Spectroscopy
2.4. Size and Distribution can be Determined via Dynamic Light Scattering. (DLS)
2.5. Experimental Methods and Animals
2.6. Dissection and Blood Collection
2.7. Preparation of Renal Tissue Homogenate
2.8. Biochemical Analyses
2.8.1. Kidney Function
2.8.2. Interleukin-6 (IL-6)
2.8.3. Immunoglobulins
2.8.4. Antioxidants and Lipid Peroxidation
2.9. Histopathology
2.10. Statistical Analysis
3. Results
3.1. AgNPs-Coated Vanillic Acid
3.2. IL-6, FBS, and HbA1c
3.3. Antioxidant and Lipid Peroxidation
3.4. Kidney Function and Serum Electrolytes
3.5. Immunoglobins
3.6. Pathology
3.6.1. Renal Tissue
3.6.2. Pancreas
4. Discussion
5. Conclusions
Funding
Declarations of Interest
Data availability
List of Abbreviations
| AgNPs | Silver nanoparticles |
| CAT | Catalase |
| DLS | dynamic light scattering |
| FBS | fasting blood sugar |
| G1 | a negative control group injection of 0.1 mol/l citrate buffer (pH 4.5). |
| G2 | a positive control group was intravenously injected with freshly prepared streptozotocin (65 mg/kg bw) in a 0.1 mol/l citrate buffer (pH 4.5). |
| G3 | was intravenously injected with freshly prepared streptozotocin (65 mg/kg bw) in a 0.1 mol/l citrate buffer (pH 4.5) and treated with (100 mg/g bw vanillic acid. |
| G4 | was intravenously injected with freshly prepared streptozotocin (65 mg/kg bw) in a 0.1 mol/l citrate buffer (pH 4.5) and treated with 100 mg/g bw AgNPs-coated vanillic acid. |
| GSH | Glutathione reduced |
| GST | Glutathione transferase |
| HbA1c | Glycated hemoglobin |
| IL-6 | Interleukin -6 |
| MDA | Malondialdehyde |
| ROS | Reactive oxygen species |
| SOD | Superoxide dismutase |
| SPSS | Statistical Package for the Social Sciences |
| STZ | Streptozotocin |
| TEM | transmission electron microscope |
References
- Aebi, H. , 1984. Catalase in Vitro. Meth. Enzymol. 105, 121–126. [CrossRef]
- Ahmed, D. , Kumar, V., Verma, A., et al., 2014. Antidiabetic, Renal/Hepatic/Pancreas/Cardiac Protective and Antioxidant Potential of Methanol/Dichloromethane Extract of Albizzia Lebbeck Benth. Stem Bark (ALEx) on Streptozotocin-Induced Diabetic Rats. BMC Complement. Alternat. Med. 14, 243-260. [CrossRef]
- Alamri, E.S. , El Rabey, H.A., Alzahrani, OR., et al., 2022. Enhancement of the Protective Activity of Vanillic Acid against Tetrachloro-Carbon (CCl4) Hepatotoxicity in Male Rats by the Synthesis of Silver Nanoparticles (AgNPs). Molecules. 28-27(23), 8308. doi.org/10. 3390. [Google Scholar]
- Al-Malki, A.L. , El Rabey, H.A., 2015. The antidiabetic effect of low doses of Moringa oleifera Lam. seeds on streptozotocin-induced diabetes and diabetic nephropathy in male rats. Biomed Res. Int. 2015. 381040. doi.org/10. 1155. [Google Scholar]
- Almutairi, F.M. , El Rabey H.A., Tayel, A.T., et al., 2020. Augmented anticancer activity of curcumin loaded fungal chitosan nanoparticles. Int. J. Biol. Macromol. 15(155), 861-867. [CrossRef]
- Al-Rubeaan, K. , Siddiqui, K., Abu Risheh, K., et al., 2011. Correlation between Serum Electrolytes and Fasting Glucose and Hb1Ac in Saudi Diabetic Patients. Biol. Trace Elem. Res. 144, (1-3), 463-468. [CrossRef]
- Armitage, W.G. , Berry, G.Y., 1987. Statistical Methods, 7th ed.; Iowa State University: Ames, IA, USA, pp. 39–63.
- Bancroft, J.D. , Stevens, A., 1996. The haematoxylin and eosin. In Theory and Practice of Histological Techniques; Churchill Livingstone: 6th ed. London, UK.
- Berne, G. , 1974. Detection of Total IgG. Clin. Chemist. 200, 61-89. doi.org/10. 1155. [Google Scholar]
- Burdus, A. , Gherasim, O., Grumezescu, A.M., et al. Review, Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview. Nanomat. 8, 681. [CrossRef]
- El Rabey, H.A. , Alamri, E.S., Alzahrani, O.R., et al., 2023. Silymarin and vanillic acid silver nanoparticles alleviate the carbon tetrachloride-induced nephrotoxicity in male rats. Int. J. Polym. Sci. 4120553. doi.org/10. 1155. [Google Scholar]
- El Rabey, H.A. , Almutairi, F.M., Alalawy, A.I., et al., 2019. Augmented control of drug-resistant Candida spp. via fluconazole loading into fungal chitosan nanoparticles. Int. J. Biol. Macromol. 141, 511-516. [CrossRef]
- El Rabey, H.A. , Al-Seeni, M.N., Bakhashwain A.S., 2017. The Antidiabetic Activity of Nigella sativa and Propolis on Streptozotocin-Induced Diabetes and Diabetic Nephropathy in Male Rats. Evidence-based Complement. Alternat. Med. 1-14. doi.org/10. 1155. [Google Scholar]
- El Rabey, H.A. , Rezk, S.M., Sakran, M.I., et al., 2021. Green coffee methanolic extract and silymarin protect against CCl4-induced hepatotoxicity in albino male rats. BMC Complement Alternat. Med. 21(1).19. [CrossRef]
- Foggensteiner, L. , Mulroy, S., Firth, J., 2001. Management of diabetic nephropathy. J. R. Soc. Med. 94, 210–217. [CrossRef]
- Forbes, J.M. , Cooper, M.E., 2013. Mechanisms of diabetic complications. Physiol. Rev. 93,137–188. doi.org/10.1152/physrev.00045. 2011. [Google Scholar]
- Habig, W. , Pabst, M., Jakoby, W., 1974. Glutathione S-Transferase: The First Enzymatic Step in Mercapturic Acid Formation. Journal of Biological Chemistry. 249, 22, 7130-7139. doi.org/10. 1016. [Google Scholar]
- Hamada, Y. , Nagasaki, H., Fuchigami, M., et al., 2013. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism, ameliorating obesity and insulin resistance in diabetic mice. Metabolism. 62(5), 734–742. [CrossRef]
- Ibrahim, O.H. , Hassan, M.A., 2018. The Use of Antidiabetic Drugs in Alzheimer’s Disease, New Therapeutic Options and Future Perspective. Pharmacol. Pharm. 9, 157-174. [CrossRef]
- Ioana, G. , Cristea, D., 2020. Silver nanoparticles for delivery purposes. In book: by Masoud Mozafari; ’Nanoengineered Biomaterials for Advanced Drug Delivery, pp. 347-371. [CrossRef]
- Jahangirian, H. , Lemraski, E.G., Webster, et al., 2017. A review of drug delivery systems based on nanotechnology and green chemistry: Green nanomedicine. Int. J. Nanomed. 12, 2957–2978. [CrossRef]
- Jans, H. , Liu, X., Austin, L., Maes, G., Huo, Q., 2009. Dynamic Light Scattering as a Powerful Tool for Gold Nanoparticle Bioconjugation and Biomolecular Binding Studies. Anal. Chem. 81(22), 9425-9432.
- Ji, G. , Sun, R., Hu, H. et. al., 2020. Vanillic acid ameliorates hyperglycemia-induced oxidative stress and inflammation in streptozotocin-induced diabetic rats. J. King Saud Univ. – Sci. 32, 2905–2911. doi.org/10.1016/j.jksus.2020.04.010.
- Khairnar, S. , Pawar, S., Patil, V., Rudrapal, M., 2020. Effect of Vanillic Acid in Streptozotocin-Induced Diabetic Neuropathy. Asian J. Biol. Sci. 9(3), 306-312. [CrossRef]
- Kumar, S. , Prahalathan, P., Raja, B., 2011. Antihypertensive and antioxidant potential of vanillic acid, a phenolic compound in l-NAME-induced hypertensive rats: A dose-dependence study. Redox Rep. 16(5), 208–215. [CrossRef]
- Liamis, G. , Liberopoulos, E., Barkas, F., Elisaf, M., 2014. Diabetes Mellitus and Electrolyte Disorders. World J. Clin. Cases. 2(10), 488–496. [CrossRef]
- Nishikimi, M. , Roa, N., Yogi, K., 1972. The Occurrence of Superoxide Anion in the Reaction of Reduced Phenazine Methosulfate and Molecular Oxygen. Biochem. Biophys. Res.Commun. 46(2), 849–854. [CrossRef]
- Oke, I.M. , Ramorobi, L.M., Mashele, S.S. Vanillic acid–Zn(II) complex: a novel complex with antihyperglycaemic and anti-oxidative activity. Journal of Pharmacy and Pharmacology, (2021), Vol 73, 1703–1714.
- Patra, J.K. , Das, G., Fraceto, L.F., et al., 2018. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 16. 71. [CrossRef]
- Raja, B. , Deepa, M.S., 2010. The protective role of vanillic acid against acetaminophen-induced hepatotoxicity in rats. J. Pharm. Res. 3, 1480–1484. [CrossRef]
- Ramudu, S. , Korivi, M., Kesireddy, N., et al., 2011. Nephro-Protective Effects of a Ginger Extract on Cytosolic and Mitochondrial Enzymes against Streptozotocin (STZ)-Induced Diabetic Complications In Rats. Chin. H. Phys. 54(2), 79-86. [CrossRef]
- Shahbandeh, M. , Moghadam, M.T., Mirnejad, R. et al., 2020. The Efficacy of AgNO3 Nanoparticles Alone and Conjugated with Imipenem for Combating Extensively Drug-Resistant Pseudomonas aeruginosa. Int. J. Nanomed. 15, 6905-6916. [CrossRef]
- Sindhu, G. , Nishanthi, E., Sharmila, R., 2015. Nephroprotective effect of vanillic acid against cisplatin induced nephrotoxicity in wistar rats: a biochemi-cal and molecular study. Environ. Toxicol. Pharmacol. 39(1), 392–404. [CrossRef]
- Tavafi, M. , 2013. Complexity of diabetic nephropathy pathogenesis and design of investigations. J. Renal. Inj. Prev. 2(2), 61-65. [CrossRef]
- Vivek, R. , Ramar, T., Muthuchelian, K., et al., 2012. Green biosynthesis of silver nanoparticles from Annona squamosa leaf extract and it’s in vitro cytotoxic effect on MCF-7 cells. Process. Biochem. 47, 2405-2410. [CrossRef]
- Wang, S. , Hou, X., Liu, Y., et al., 2013. Serum Electrolyte Levels in Relation to Macrovascular Complications in Chinese Patients with Diabetes Mellitus. Cardiovasc. Diabetol. 12, 146-155. [CrossRef]
- Younas, M. , Ahmad, M.A., Jannat, F.T., et al., 2021. Chapter 18, “Role of silver nanoparticles in multifunctional drug, in Nanomedicine Manufacturing and Applications”. Elsevier Inc. p. 298-319.
- Zamani, H. , Moradshahi, A., 2013. Synthesis and coating of nanosilver by vanillic acid and its effects on Dunaliella salina Teod, Mol. Biol. Res. Commun. 2(3), 47-55. https://mbrc.shirazu.ac.ir/article_1571_346.
- Zhang, X. , Liu, Z., Shen, W., Gurunathan, S., 2016. Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches. Int. J. Mol. Sci. 17, 1534-1543. [CrossRef]
- Zhang, X.F. , Liu, Z.G., Shen, W., Gurunathan, S., 2016 Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches. Int. J. Mol. sci. 17(9), 1534. [CrossRef]





| Parameters | Statistical Tests | G1 (Negative control) | G2 (Positive control) | G3 (Treated with vanillic acid) | G4 (Treated with AgNPs of vanillic acid) |
|---|---|---|---|---|---|
| FBS。(mg/dL) | Mean ± SE | 87.0 ± 0.96d | 281.66 ± 1.83a | 202.33 ± 2.74b | 167.66 ± 2.07c |
| LSD0.05 = 6.987 | |||||
| T-test | - | -69.80*** | 20.31*** | 44.60*** | |
| HbA1C。(%) | Mean ± SE | 5.03 ± 0.05d | 7.26 ± 0.09a | 6.46 ± 0.12b | 6.00 ± 0.07c |
| LSD0.05 = 0.209 | |||||
| T-test | - | -26.48*** | 21.90*** | 13.78*** | |
| IL-6 (pg/mL) | Mean ± SE | 22.33 ± 0.91d | 79.00 ± 2.98a | 60.66 ± 1.47b | 39.66 ± 0.91c |
| LSD0.05 = 3.618 | |||||
| T-test | - | -32.77*** | 13.58*** | 18.56*** |
| Parameter. | Statistical Tests | G1 (Negative control) | G2 (Positive control) | G3 (Treated with vanillic acid) | G4 (Treated with AgNPs-coated vanillic acid) |
|---|---|---|---|---|---|
| GST。(U/g kidney tissue homogenate) | Mean ± SE | 111.00 ± 3.28a | 23.33 ± 1.28c | 74.33 ± 4.10b | 96.66 ± 4.00b |
| LSD 0.05 = 11.442 | |||||
| T-test | - | 43.59*** | -9.48*** | -14.79*** | |
| SOD。(U/g kidney tissue homogenate) | Mean ± SE | 126.00 ± 3.84a | 44.66 ± 3.39c | 73.33 ± 1.28b | 89.66 ± 2.74d |
| LSD 0.05 = 30.981 | |||||
| T-test | - | 31.71*** | -8.44*** | -9.31*** | |
| CAT。(U/g kidney tissue homogenate) | Mean ± SE | 3.46 ± 0.11a | 0.67 ± 0.02d | 1.43 ± 0.04c | 2.52 ± 0.03b |
| LSD 0.05 = 0.215 | |||||
| T-test | - | 23.52*** | -17.52*** | -39.94*** | |
| MDA(nmol/ g. kidney tissue) | Mean ± SE | 0.33 ± 0.01d | 1.62 ± 0.02a | 0.90 ± 0.00b | 0.70 ± 0.02c |
| LSD 0.05 = 0.051 | |||||
| T-test | - | -70.65*** | 20.95*** | 33.37*** |
| Parametersmg/dl | Statistical Tests | G1 (Negative control) | G2 (Positive control) | G3 (Treated with vanillic acid) | G4 (Treated with AgNPs of vanillic acid) |
|---|---|---|---|---|---|
| Urea | Mean ± SE | 22.66±0.42d | 76.00±1.31a | 44.00±1.31b | 37.00±0.73c |
| LSD0.05=2.009 | |||||
| T-test | - | -50.59*** | 43.81*** | 40.36*** | |
| Creatinine | Mean ± SE | 0.63±0.02d | 1.53±0.02a | 1.10±0.03b | 0.86±0.02c |
| LSD0.05=0.075 | |||||
| T-test | - | -24.64*** | 20.55*** | 31.62*** | |
| Uric acid | Mean ± SE | 3.90±0.09a | 3.96±0.11a | 3.9±0.11a | 3.90±0.20a |
| LSD0.05=0.437 | |||||
| T-test | - | -0.33 NS | 0.19 N | 0.72 NS | |
| Na+ | Mean ± SE | 145.66±0.55a | 117.00±0.73d | 126.00±0.36c | 133.66±1.11b |
| LSD0.05=1.501 | |||||
| T-test | - | 37.71*** | -24.64*** | -19.76*** | |
| K+ | Mean ± SE | 4.93±0.05d | 6.93±0.09a | 5.73±0.05b | 5.36±0.02c |
| LSD0.05=0.208 | |||||
| T-test | - | -13.69*** | 09.48*** | 20.61*** | |
| Ca++ | Mean ± SE | 11.50±0.07a | 07.22±0.04d | 08.30±0.07c | 09.69±0.02b |
| LSD0.05=0.159 | |||||
| T-test | - | 60.32*** | -19.12*** | -91.64*** |
| Parameters | Statistical Tests | G1 (Negative control) | G2 (Positive control) | G3 (Treated with vanillic acid) | G4 (Treated with AgNPs of vanillic acid) |
|---|---|---|---|---|---|
| IgA mg/L | Mean ± SE | 103.33 ± 3.65d | 342.33 ± 4.15a | 311.33 ± 2.01b | 281.66 ± 3.90c |
| LSD 0.05 = 9.865 | |||||
| T-test | - | -64.49*** | 5.08*** | 14.22*** | |
| IgM mg/L | Mean ± SE | 131.00 ± 1.46d | 350.33 ± 4.76a | 321.33 ± 2.69b | 302.00 ± 2.03c |
| LSD0.05 = 6.293 | |||||
| T-test | - | -64.64*** | 9.70*** | 12.48*** | |
| IgG mg/L | Mean ± SE | 526.33 ± 02.59c | 735.66 ± 08.58a | 750.33 ± 24.45a | 622.66 ± 01.47b |
| LSD 0.05 = 35.916 | |||||
| T-test | - | -28.86*** | -00.84 NS | 11.79*** |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).